# Cemdisiran PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cemdisiran

> The PDUFA target action date for cemdisiran, sponsored by REGENERON PHARMACEUTICALS, INC. (REGN), is Q1 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the cemdisiran PDUFA date?

The PDUFA target action date for cemdisiran, sponsored by REGENERON PHARMACEUTICALS, INC. (REGN), is Q1 2027. Status: scheduled. Press release filed with the SEC (EX-99): "Submit New Drug Application (NDA) for cemdisiran (C5 siRNA therapy) in myasthenia gravis (first quarter 2026) and FDA decision on NDA (fourth quarter 2026/first quarter 2027)" Last confirmed January 30, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/cemdisiran)

Source: Press release filed with the SEC (EX-99), accession 0000872589-26-000004, https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/exhibit991q42025.htm (retrieved 2026-11-12). Last confirmed 2026-01-30. Cite: https://sec-api.dev/pdufa/cemdisiran#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | cemdisiran |
| Codes |  |
| Sponsor | REGENERON PHARMACEUTICALS, INC. (REGN) https://sec-api.dev/companies/regn/catalysts |
| Indications |  |
| Modality | sirna |
| FDA designations | none disclosed |

## Timeline

### Q2 2026: NDA/BLA acceptance

- Status: scheduled. Date confidence: quarter.
- First seen 2026-04-29, last confirmed 2026-04-29.
- Press release filed with the SEC (EX-99) (accession 0000872589-26-000014): "NDA acceptance is anticipated in the second quarter of 2026 with an FDA decision expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/exhibit991q12026.htm

### Nov 2026: PDUFA date

- Status: scheduled. Date confidence: month.
- First seen 2026-07-30, last confirmed 2026-07-30.
- Press release filed with the SEC (EX-99) (accession 0000872589-26-000023): "The FDA will review the New Drug Application (NDA) under priority review with a target action date in November 2026, following use of a Priority Review Voucher." https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/exhibit991q22026.htm

### Q1 2027: PDUFA date

- Status: scheduled. Date confidence: quarter.
- First seen 2026-01-30, last confirmed 2026-01-30.
- Press release filed with the SEC (EX-99) (accession 0000872589-26-000004): "Submit New Drug Application (NDA) for cemdisiran (C5 siRNA therapy) in myasthenia gravis (first quarter 2026) and FDA decision on NDA (fourth quarter 2026/first quarter 2027)" https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/exhibit991q42025.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cemdisiran.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Cemdisiran PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cemdisiran

```bibtex
@misc{secapidev_pdufa_cemdisiran_20261116,
  title        = {Cemdisiran PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cemdisiran}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cemdisiran_20261116","title":"Cemdisiran PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cemdisiran","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
